A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research

PROJECT SUMMARY/ABSTRACT The Center for International Blood and Marrow Transplant Research (CIBMTR) is a clinical research program dedicated to addressing important issues in the field of Hematopoietic Cell Transplantation (HCT) and Adoptive Cell Therapy (ACT). CIBMTR maintains a large outcomes registry with information for >625,000 HCT/ACT patients in treatment centers in the United States and internationally and provides statistical support and scientific expertise for analyzing those data. A separately funded research repository of biospecimens linked to these clinical data is available for a large subset of HCT recipients. CIBMTR recently began collecting patient- reported outcomes (PROs), information collected directly from the patient to understand their experience of the therapy and its impact on their quality of life and links these data to clinical outcomes. CIBMTR is dedicated to supporting research to inform clinical practice for patients with cancer and non-malignant blood disorders. Use of the registry by thousands of investigators around the world during the current and previous funding cycles has contributed to >1,700 publications on important issues. This knowledge has been disseminated to multiple stakeholders to speed innovation across our field and improve outcomes for our patients. CIBMTR will continue to build on the infrastructure made possible by the support provided by the NIH, and in this application proposes to enhance this registry and to advance its utility through the following specific aims: Resource Development: To maintain and enhance the scope and broad usability of the registry by adding new indications (e.g., solid tumors, infection) and data types (e.g., PROs) and optimizing the data lifecycle. Resource Utilization: To support novel research in hematological malignant and non-malignant disorders and solid tumors, in a timely manner through observational research; correlative studies (e.g., biospecimens, PRO); supporting other data initiatives (especially federally funded) and clinical trial networks; and building collaborative relationships.